News & Updates

ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.

Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.

A recent study in UK has shown a significant proportion of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) initiating direct-acting antiviral (DAA) therapy, resulting in improvements in sustained virological response (SVR) rates.

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Vaccination against COVID-19 provides survival benefits to cancer patients receiving immune checkpoint inhibitors (ICIs), as shown in a recent study.